18336-75-9

Basic information

• Product Name: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE
• Synonyms: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE
• CAS NO: 18336-75-9
• Molecular Formula: C₁₁H₁₁N₃O₂
• Molecular Weight: 217.22
• Mol File: 18336-75-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 173-175°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.244 g/cm³
• Refractive Index: 1.586
• PKA: 10.94±0.10(Predicted)
• CAS DataBase Reference: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(18336-75-9)
• EPA Substance Registry System: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(18336-75-9)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 18336-75-9(Hazardous Substances Data)

Usage

General Description

5-Methyl-3-phenyl-4-isoxazolecarbohydrazide, also known as Methylphenidate, is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by affecting certain chemicals in the brain and nerves that contribute to impulse control and hyperactivity. Methylphenidate is available in both immediate-release and extended-release forms, and it is typically taken orally. Common side effects of Methylphenidate include insomnia, decreased appetite, and increased heart rate, and it may also have the potential for abuse and dependence. It is important to take Methylphenidate exactly as prescribed and to follow all directions provided by a healthcare professional.

InChI:InChI=1/C11H11N3O2/c1-7-9(11(15)13-12)10(14-16-7)8-5-3-2-4-6-8/h2-6H,12H2,1H3,(H,13,15)

Upstream product

• 932-90-1 Benzaldoxime 
• 100-52-7 benzaldehyde 
• 1143-82-4 ethyl 5-methyl-3-phenylisoxazole-4-carboxylate 
• 1136-45-4 5-methyl-3-phenylisoxazol-4-carboxylic acid 
• 16883-16-2 5-methyl-3-phenylisoxazole-4-carbonyl chloride 

Downstream Products

• 68055-50-5 1,2-Bis(3'-phenyl-5'-methyl-4'-isoxazolyl)hydrazine 
• 21011-55-2 N'-(5-methyl-3-phenyl-isoxazole-4-carbonyl)-hydrazinecarbodithioic acid ethyl ester 
• 68055-51-6 2-furan-2-yl-5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole 
• 68055-54-9 2-(2-furan-2-yl-vinyl)-5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole 
• 68055-52-7 2-(5-bromo-furan-2-yl)-5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole 
• 68055-53-8 2-(5-methyl-3-phenyl-isoxazol-4-yl)-5-(5-nitro-furan-2-yl)-[1,3,4]oxadiazole 
• 68055-56-1 2,5-bis-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole 
• 68055-55-0 2-(5-methyl-3-phenyl-isoxazol-4-yl)-5-[2-(5-nitro-furan-2-yl)-vinyl]-[1,3,4]oxadiazole 
• 68055-57-2 2-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazole 
• 21169-65-3 5-methyl-3-phenyl-1,2-oxazole-4-amine 
• 21169-66-4 N-(5-methyl-3-phenyl-isoxazol-4-yl)-acetamide 
• 21215-60-1 4-amino-5-(5-methyl-3-phenyl-isoxazol-4-yl)-2,4-dihydro-[1,2,4]triazole-3-thione 
• 21011-57-4 5-(5-methyl-3-phenyl-isoxazol-4-yl)-4-phenyl-2,4-dihydro-[1,2,4]triazole-3-thione 
• 21011-58-5 [5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]thiadiazol-2-yl]-phenyl-amine 

Relevant articles and documents

A New Series of 1,3,4-Oxadiazole Linked Quinolinyl-Pyrazole/Isoxazole Derivatives: Synthesis and Biological Activity Evaluation

Abstract: A series of 1,3,4-oxadiazole bridged pyrazole/isoxazole bearing quinoline derivatives has been designed and synthesized by a clean and convenient method. Structures of the newly synthesized compounds have been confirmed by FTIR, 1H and 13C NMR, and HRMS spectral data. The titled compounds have been evaluated for their molecular docking guided antimicrobial and anti-inflammatory activity. One of 1,3,4-oxadiazole bridged quinolinyl-pyrazole derivatives has interacted efficiently with E. Coli protein (PDB file: 1KZN), and has been characterized by good antimicrobial activity against the majority of the tested pathogens. Another product has exhibited excellent anti-inflammatory activity.

ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES

The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula (I) wherein R1 is hydrogen, halogen, aryl, heterocyclyl, heteroaryl, cyano, lower alkyl, -(CH2)n-cycloalkyl, -(CH2)n/